GlassScriptPhysician profile
Matthew Brian Donovan
NPI 1366804858
$15,075.38
in general payments reported to CMS, 2019-2025
16 companies · $2,751 in 2025
The $2,751 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $726 · 2022: $855 · 2023: $10K · 2024: $369 · 2025: $2,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,940 · Consulting Fee: $2,164 · Food and Beverage: $1,361 · Travel and Lodging: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,940.00 |
| Consulting Fee | $2,163.75 |
| Food and Beverage | $1,360.67 |
| Travel and Lodging | $1,030.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $10,237.75 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $2,807.82 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $647.59 | 2021-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $332.38 | 2021-2025 | Vabysmo |
| Notal Vision, INC. | $226.88 | 2021-2024 | Foresee Home |
| Astellas Pharma US INC | $160.53 | 2023-2025 | Izervay |
| Cardinal Health 108 LLC | $125.00 | 2022 | |
| Allergan, INC. | $123.26 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $114.64 | 2021-2022 | |
| Harrow Eye, LLC | $81.11 | 2024-2025 | Iheezo |
| Biotissue Holdings INC. | $47.60 | 2022 | |
| Horizon Therapeutics Plc | $42.12 | 2021 | |
| Oyster Point Pharma, INC. | $38.93 | 2022 | |
| Bausch & Lomb Americas INC. | $38.52 | 2022-2024 | Xipere |
| Novartis Pharmaceuticals Corporation | $34.81 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $16.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.